Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
7.2(c) 7.45(c) 7.7(c) 7.5(c) 7.75(c) Last
146 715 172 001 657 492 586 414 125 787 Volume
+2.13% +3.47% +3.36% -2.60% +3.33% Change
More quotes
Financials ($)
Sales 2017 0,29 M
EBIT 2017 -59,4 M
Net income 2017 -59,1 M
Finance 2017 40,9 M
Yield 2017 -
Sales 2018 0,38 M
EBIT 2018 -68,7 M
Net income 2018 -67,0 M
Finance 2018 74,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 291x
EV / Sales2018 135x
Capitalization 126 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Is portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CIDARA THERAPEUTICS INC
04/25 CIDARA THERAPEUTICS : Announces Promotion of Taylor Sandison, M.D., M.P.H., to C..
04/17 CIDARA THERAPEUTICS : to Present Data on Novel Antifungal CD101 and Cloudbreak A..
04/06 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Regulation FD Disclosure
04/06 CIDARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and E..
04/05 INSIDER TRADING ACTIVITY CIDARA THER : CDTX) – insider Bought 12,500 share..
04/05 INSIDER TRADING ACTIVITY CIDARA THER : CDTX) – CEO Bought 12,900 shares of..
03/31 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Entry into a Material Def..
03/31 CIDARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K..
03/30 CIDARA THERAPEUTICS : Awarded $6.9 Million Grant from CARB-X to Advance Developm..
03/29 Cidara Therapeutics to Host Investor Day on April 6, 2017
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/26BLOCK TRADE: $CDTX 300,000 shares @ $7.50 [13:20:51] #BlockTradeAlert 
04/26#TrendReversalUp $CDTX CIDARA THERAPEUTICS #TradeIdeas via ?  
04/26The Antimicrobial Resistance Crisis
1
04/25Want automatic email alerts for $TIN $CME $CDTX $WTW $BIO? Subscribe to Marke.. 
04/25$CDTX: Cidara Therapeutics announces that Taylor Sandison, M.D., has been nam.. 
More tweets
Qtime:10
News from SeekingAlpha
04/26 The Antimicrobial Resistance Crisis
04/07 WHAT TO WATCH IN Q2 : Upcoming Healthcare Data Releases
04/06 Cidara Therapeutics (CDTX) Investor Presentation - Slideshow
03/15 Cidara Therapeutics misses by $0.09
02/21 Midday Gainers / Losers
Advertisement
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Full-screen chart
Technical analysis trends CIDARA THERAPEUTI...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 12,9 $
Spread / Average Target 71%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary & General Counsel
Taylor Sandison Chief Medical Officer & VP-Clinical Development
Theodore R. Schroeder Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS IN..-27.88%126
AMGEN, INC.11.29%119 744
CELGENE CORPORATION7.10%96 445
GILEAD SCIENCES, INC.-4.23%89 650
REGENERON PHARMACEUTIC..-0.13%38 968
ACTELION LTD26.44%29 633
More Results